Hypoglossal nerve

Inspire Medical Systems, Inc. Announces Events at SLEEP 2023, the 37th Annual Meeting of the Associated Professional Sleep Societies

Retrieved on: 
Monday, June 5, 2023
SRS, AASM, Hypoglossal nerve, Obstructive sleep apnea, Somnolence, UAS, STAR, Sleep Research Society, American Academy, OSA, Doctor of Philosophy, American Academy of Sleep Medicine, Patient, Physician, Survival, Associated, NYSE, Pharmaceutical industry, Nursing, Inspiration, MD

SLEEP 2023 is the 37th annual meeting of the Associated Professional Sleep Societies (APSS), a joint venture of the American Academy of Sleep Medicine (AASM) and the Sleep Research Society (SRS).

Key Points: 
  • SLEEP 2023 is the 37th annual meeting of the Associated Professional Sleep Societies (APSS), a joint venture of the American Academy of Sleep Medicine (AASM) and the Sleep Research Society (SRS).
  • “We are thrilled to return to SLEEP and highlight our recent innovative technology enhancements to the Inspire platform and share compelling clinical data further demonstrating the real-world efficacy of our treatment,” said Tim Herbert, President and CEO.
  • There will be multiple sessions at SLEEP highlighting the outcomes of Inspire therapy, including the Year In Review and Alternative Therapies for Sleep Apnea on Saturday, June 3rd.
  • 2:45 – 3:00 pm: Patient-Reported Experience with Hypoglossal Nerve Stimulation for Obstructive Sleep Apnea – Influence of Symptom Improvements (Marcel Braun, PhD, et al.)

Signifier Medical Technologies Reaches a Wider Patient Population with FDA Approval to Remove Dental Contraindications for eXciteOSA

Retrieved on: 
Wednesday, February 22, 2023
Science, Other Science, Biotechnology, Health, FDA, Medical Devices, Dental, Clinical Trials, OSA, Snoring, Observational study, DDS, Veteran, Patient, Education, Jewellery, Hypoglossal nerve, Contraindication, VA, Health technology, Pharmaceutical industry, Dentistry

Signifier Medical Technologies LLC (“Signifier” or the “Company”), a Boston-based medical technology company, announces the FDA approval to remove dental contraindications for eXciteOSA.

Key Points: 
  • Signifier Medical Technologies LLC (“Signifier” or the “Company”), a Boston-based medical technology company, announces the FDA approval to remove dental contraindications for eXciteOSA.
  • Based on an observational study conducted by Signifier Medical, the data demonstrated no significant difference in the occurrence of eXciteOSA side effects amongst those with intraoral metal and those without intraoral metal dental work.
  • “A large number of Veterans were previously deemed ineligible for eXciteOSA for mild OSA/simple snoring because of the dental contraindications.
  • This study demonstrates the low-risk profile of eXciteOSA -- a novel medical therapy that was authorized in the FDA De Novo process.

Neuromodulation Devices Markets, 2029 - ResearchAndMarkets.com

Retrieved on: 
Monday, November 28, 2022
Medical Devices, Health, Neurology, Other Science, Science, Biotechnology, Webbed toes, Hypoglossal nerve, Hospital, Incidence, TENS, Neuromodulation, Gastroenterology, Degenerative disease, Pain management, SCS, Weaning, Stroke, Epilepsy, Chronic pain, Patient, Anxiety, Government, OSA, Ageing, Heart failure, Parkinson's disease, Transcutaneous electrical nerve stimulation, Obesity, Rheumatoid arthritis, CNS, Autoimmune disease, Central sleep apnea, Obstructive sleep apnea, Functional electrical stimulation, Diabetes, Mood disorder, Obsessive–compulsive disorder, Multiple sclerosis, Urinary incontinence, Urology, OCD, NMES, Movement disorders, Central nervous system, Investment, Pharmaceutical industry, Medical device, Beauty salon, Medicine, Dystonia, Depression, Gastroparesis

The "Neuromodulation Devices Global Market- Forecast To 2029" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Neuromodulation Devices Global Market- Forecast To 2029" report has been added to ResearchAndMarkets.com's offering.
  • The treatment delivered by neuromodulation devices brings about life-changing transformation in patients who fail to get better by traditional approaches.
  • Based on the product, the neuromodulation global market is segmented into invasive neuromodulation devices and non-invasive neuromodulation devices.
  • Among these, invasive neuromodulation devices segment accounted for the highest revenue in 2022 and is expected to grow at an early teen CAGR from 2022 to 2029.

LivaNova Announces First Patient Implanted in OSPREY Clinical Study for Patients Coping with Obstructive Sleep Apnea

Retrieved on: 
Thursday, February 24, 2022
Biotechnology, FDA, Health, Other Health, Surgery, Other Science, Mental Health, Research, Medical Devices, General Health, Hospitals, Science, Clinical Trials, Cardiology, Depression, Health, Airway obstruction, Traffic, LivaNova, Critical care, Mask, PLC, Head, Death, Risk, Diabetes, University, Annual report, Sleep apnea, Stroke, Safety, Tongue, Randomized controlled trial, Tampa Bay, Heart failure, Trial of the century, IPG, Hope, RCT, Adult, Continuous positive airway pressure, Morton Plant Hospital, OSA, Principal, News, IDE, Sleep, Hypertension, Hypoglossal nerve, Patient, LIVN, CPAP, University of California, Obstructive sleep apnea, Hospital, Medical device, Pharmaceutical industry, Medicine, LivaNova, BayCare Health System, LIVANOVA, BAYCARE HEALTH SYSTEM

LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology and innovation company, today announced the first patient implanted in the investigational device exemption (IDE) clinical study, Treating Obstructive Sleep Apnea using Targeted Hypoglossal Neurostimulation ( OSPREY ).

Key Points: 
  • LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology and innovation company, today announced the first patient implanted in the investigational device exemption (IDE) clinical study, Treating Obstructive Sleep Apnea using Targeted Hypoglossal Neurostimulation ( OSPREY ).
  • The first OSPREY patient was implanted by Dr. Mitchell Miller at BayCares Morton Plant Hospital in Clearwater, Florida.
  • Throughout the study, independent statisticians will conduct interim data analyses to determine predictive probability of success for OSPREY.
  • Clinical consequences and economic costs of untreated obstructive sleep apnea syndrome World Journal of Otorhinolaryngology-Head and Neck Surgery 2015; 1: 17-27.

IDTechEx Forecasts Peripheral Nerve Stimulation Market to Grow at 35% CAGR, 2019-2029

Retrieved on: 
Wednesday, July 3, 2019
Nervous system, Organ systems, Hypoglossal nerve, Motor system, Peripheral nervous system, Branches of biology

Please refer to the IDTechEx market research report " Bioelectronic Medicine 2019-2029 " for more information.

Key Points: 
  • Please refer to the IDTechEx market research report " Bioelectronic Medicine 2019-2029 " for more information.
  • IDTechEx has previously reported that the treatment of chronic diseases will be key to the forecasted $60 billion market.
  • The recent regulatory approvals, particularly in devices that stimulate nerves in the peripheral nervous system, attest to this conclusion.
  • Stimulation of the hypoglossal nerve by the device moves the tongue to clear the airway, thusremoving the obstruction.